고형암 (전체)

432개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved432 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Raludotatug deruxtecan (Raludotatug deruxtecan)

Carcinoma, Non-Small-Cell Lung · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 7Status Recruiting
AntibodyLimited DatastaleRochePhase 1

trastuzumab vc-seco-DUBA (SYD985, SYD985 (trastuzumab vc-seco-DUBA))

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#monoclonal-antibody#Roche
Trials 7Status Active
CGTLimited DatastaleUTC Therapeutics Inc.Preclinical

Anti-HER2 CAR-T cells (Anti-HER2 CAR-T cells)

HER2-positive Advanced Malignant Solid Tumors · HER2

#HER2#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated favezelimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#UrothelialNeoplasms+1
Trials 6Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Plus Cadonilimab)

Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BileDuctAdenocarcinomaNon-Resect+2
Trials 6Status Active
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Gemcitabine)

Radical Cystectomy; Urothelial Carcinoma · Radical Cystectomy

#RadicalCystectomy#ADC#Approved#antibody-drug-conjugate#UrothelialCarcinoma+1
Trials 6Status Active
ADCLimited DatastaleMing-Yuan ChenPhase 3

Neoadjuvant and Adjuvant Becotatug Vedotin (Neoadjuvant and Adjuvant Becotatug Vedotin)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#LocallyAdvancedHeadandNeckSquamo#ADC#Phase3#antibody-drug-conjugate#Ming-Yuan
Trials 6Status Recruiting
CGTLimited DatastaleTILT Biotherapeutics Ltd.Phase 2

TILT-123 (TILT-123)

Melanoma; Head and Neck Squamous Cell Carcinoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR-GD2 (4SCAR-GD2)

Solid Tumor · GD2

#GD2#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 5Status Recruiting
AntibodyLimited DatastaleAravive, Inc.Phase 2

Batiraxcept (Batiraxcept)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Aravive
Trials 5Status Discontinued
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Boserolimab (Boserolimab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 5Status Recruiting
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Phase 1

CDH17 CAR-T (CDH17 CAR-T)

Biliary Tract Cancer; Colorectal Carcinoma · Biliary Tract Cancer

#BiliaryTractCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Recruiting
CGTLimited DatastaleEssen BiotechPhase 1

Mesothelin-directed CAR-T cells (Mesothelin-directed CAR-T cells)

Solid Tumor, Adult · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Active
AntibodyLimited DatastaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#monoclonal-antibody#OvarianCancer+2
Trials 5Status Discontinued
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

sigvotatug vedotin (sigvotatug vedotin)

Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small Cell Lung

#CarcinomaNon-SmallCellLung#ADC#Phase1#antibody-drug-conjugate#Carcinoma+3
Trials 5Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 4Status Recruiting
AntibodyLimited DatastaleEisai Inc.Phase 2

Farletuzumab ecteribulin (Farletuzumab ecteribulin)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase2#monoclonal-antibody#Eisai
Trials 4Status Recruiting
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

Icrucumab (Icrucumab)

Colon Cancer; Rectal Cancer · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#monoclonal-antibody#ColonCancer+2
Trials 4Status Active
AntibodyLimited DatastaleAstraZenecaPhase 3

MEDI4736+Tremelimumab (MEDI4736+Tremelimumab)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#monoclonal-antibody#AstraZeneca
Trials 4Status Active
CGTLimited DatastaleAllife Medical Science and Tech…Phase 1

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

Solid Tumor · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Active

6 / 22 pages

← PreviousNext →